Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 18/20 | 0.52 |
| ▸ | MMP13 | P45452 | 18/20 | 0.52 |
| ▸ | MMP2 | P08253 | 2/20 | 0.52 |
| ▸ | MMP3 | P08254 | 2/20 | 0.52 |
| ▸ | MMP9 | P14780 | 2/20 | 0.52 |
| ▸ | MMP8 | P22894 | 2/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.52 |
| ▸ | MMP14 | P50281 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7208148 | 0.92 | MMP1 (0.52) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7213095 | 0.90 | MMP1 (0.49) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7208607 | 0.90 | MMP1 (0.52) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7209196 | 0.89 | MMP1 (0.53) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7209180 | 0.88 | MMP1 (0.57) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7209154 | 0.88 | MMP1 (0.47) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7208630 | 0.81 | MMP13 (0.56) | MMP1MMP13MMP2MMP9MMP14 | |
| SCHEMBL7212961 | 0.80 | MMP1 (0.48) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL3624640 | 0.80 | MMP1 (0.42) | MMP1MMP13MMP2MMP3MMP9 | |
| SCHEMBL7212977 | 0.79 | MMP1 (0.47) | MMP1MMP13MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 651 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1181285-B1 | 3-(ARYLSULFONYLAMINO)-TETRAHYDROFURAN-3-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PROD INC (US) | 2003-10-08 | — | — | EP | claimed |
| US-6342521-B1 | DRUGS FOR TREATMENT OF ARTHRITIS | PFIZER INC. | 2002-01-29 | — | — | US | claimed |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-12037404-B2 | Human monoclonal antibodies against EphA4 and their use | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-07-16 | — | — | US | disclosed |
| EP-2534153-B2 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO}METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE | PFIZER (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240083855-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| EP-3590932-B1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY INC (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-4166558-A1 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4- [(METHYLAMINO)METHYL]PHENYL}-1 ,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3- CD]INDOL-6-ONE | Pfizer Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20220251066-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2022-08-11 | — | — | US | disclosed |
| WO-2001098277-A2 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001094353-A1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2001-12-13 | — | — | WO | disclosed |
| EP-1150973-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001053289-A1 | ANTICANCER COMPOUND AND ENANTIOMER SEPARATION METHOD USEFUL FOR SYNTHESIZING SAID COMPOUND | PFIZER PRODUCTS INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| US-6258824-B1 | TREATMENT OF HYPERPROLIFERATIVE DISEASES, SUCH AS CANCERS, IN MAMMALS. THIS INVENTION ALSO RELATES TO A PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS. | PFIZER INC. | 2001-07-10 | — | — | US | disclosed |
| EP-1106612-A1 | Quinoline derivatives useful for inhibiting farnesyl protein transferase | Pfizer Products Inc. (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2001040217-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2000073294-A2 | 3-(ARYLSULFONYLAMINO)-TETRAHYDROFURAN-3-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PRODUCTS INC. (US) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000047574-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214963-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | MMP1 3955/4885MMP13 4604/4885MMP2 4086/4885 |
| US-20240083855-A1 | JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE | ALK, JAK2, JAK1 | MMP1 2298/4885MMP13 2440/4885MMP2 2512/4885 |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | MMP1 2061/4885MMP13 4280/4885MMP2 3813/4885 |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | MMP1 2061/4885MMP13 4280/4885MMP2 3813/4885 |
| US-20220251066-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | MMP1 3955/4885MMP13 4604/4885MMP2 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.